Patient leaflet - XELCIP 150 MG FILM-COATED TABLETS
1. what xelcip is and what it is used for
Xelcip belongs to the group of medicines called „cytostatic agents“, which stop the growth of cancer cells. Xelcip contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).
Xelcip is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Xelcip is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.
Xelcip may be used either alone or in combination with other medicines.
Also, you need to be particularly careful if you are taking any of the following:
-
– gout medicines (allopurinol),
-
– blood-thinning medicines (coumarin, warfarin),
-
– medicines for seizures or tremors (phenytoin).
-
– interferon alpha
-
– radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, cisplatin, irinotecan),
-
– medicines used to treat folic acid deficiency.
Taking Xelcip with food and drink:
You should take Xelcip no later than 30 minutes after meals.
Pregnancy, breast-feeding and fertility:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You must not take Xelcip if you are pregnant or think you might be.
You should not breast-feed if you are taking Xelcip.
You should not breast-feed if you are taking Xelcip and for 2 weeks after the last dose.
If you are a woman who could become pregnant you should use effective contraception during treatment with Xelcip and for 6 months after the last dose.
If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with Xelcip and for 3 months after the last dose.
Driving and using machines:
Xelcip may make you feel dizzy, nauseous or tired. It is therefore possible that Xelcip could affect your ability to drive a car or operate machines.
Xelcip contains lactose monohydrate and sodium:
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
2. What you need to know before you take Xelcip
3. How to take Xelcip
Do not take Xelcip:
-
– if you are allergic (hypersensitive) to capecitabine or any of the other ingredients of this medicine (listed in section 6). You must inform your doctor if you know that you have an allergy or over-reaction to this medicine.
-
– if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines such as fluorouracil),
-
– if you are pregnant or breast-feeding,
-
– if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia),
-
– if you have severe liver or kidney problems,
-
– if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD) (complete DPD deficiency),
-
– if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Warnings and precautions:
Talk to your doctor or pharmacist before taking Xelcip, if you
-
– know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)
-
– if you have a family member who has a partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD)
-
– have liver or kidney diseases
-
– have or had heart problems (for example an irregular heartbeat or pain to the chest jaw and back brought on by physical effort and due to problems with the blood flow to the heart)
-
– have brain diseases (for example cancer that has spread to the brain, or nerve damage (neuropathy)
-
– have calcium imbalances (see in blood tests)
-
– have diabetes
-
– cannot keep food or water in your body because of severe nausea and vomiting
-
– have diarrhoea
-
– are or become dehydrated
-
– have imbalances of ions in your blood (electrolyte imbalances, seen in tests)
-
– have a history of eye problems as you may need extra monitoring of your eyes
-
– have a severe skin reaction.
DPD deficiency:
DPD deficiency is a genetic condition that is not usually associated with health problems unless you receive certain medicines. If you have DPD deficiency and take Capecitabine tablets, you are at an increased risk of severe side effects (listed under section 4 Possible side effects). It is recommended to test you for DPD deficiency before start of treatment. If you have no activity of the enzyme you should not take Capecitabine tablets. If you have a reduced enzyme activity (partial deficiency) your doctor might prescribe a reduced dose. If you have negative test results for DPD deficiency, severe and life-threatening side effects may still occur.
Children and adolescents
Xelcip is not indicated in children and adolescents. Do not give Xelcip to children and adolescents.
Other medicines and Xelcip:
Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.
You must not take brivudine (an anti-viral medicine for the treatment of shingles or chickenpox) at the same time as capecitabine treatment (including during any rest periods when you are not taking any capecitabine tablets).
If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take capecitabine. See also section “Do not take Capecitabine tablets”.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Xelcip should only be prescribed by a doctor experienced in the use of anticancer medicines.
Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Xelcip is based on your body surface area. This is calculated from your height and weight. The recommended dose for adults is 1250 mg/m2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.
Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.
-
– Take the tablets morning and evening as prescribed by your doctor. – Take the tablets within 30 minutes after the end of a meal
(breakfast and dinner) and swallow whole with water. Do not crush or cut tablets. If you cannot swallow capecitabine tablets whole, tell your healthcare provider.
-
– It is important that you take all your medicine as prescribed by your doctor.
Xelcip tablets are usually taken for 14 days followed by a 7day rest period (when no tablets are taken). This 21 day period is one treatment cycle.
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
If you take more Xelcip than you should
If you take more Xelcip than you should contact your doctor as soon as possible before taking the next dose.
You might get the following side effects if you take a lot more capecitabine than you should: feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.
If you forget to take Xelcip
Do not take the missed dose. Do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.
If you stop taking Xelcip
There are no side-effects caused by stopping treatment with Xelcip. In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping Xelcip might require that your doctor adjusts your anticoagulant dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Xelcip immediately and contact your doctor if any of these symptoms occur:
-
- Diarrhoea: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.
-
- Vomiting: if you vomit more than once in a 24-hour time period.
-
- Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
21085210
-
- Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
-
- Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands and/or feet.
-
- Fever: if you have a temperature of 38°C or greater.
-
- Infection: if you experience signs of infection caused by bacteria or virus, or other organisms.
-
- Chest pain: if you experience pain localised to the centre of the chest, especially if it occurs during exercise.
-
- Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
neutropenia, and neurotoxicity).
If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.
If severe stomatitis (sores in your mouth and/or throat), mucosal inflammation, diarrhoea, neutropenia (increased risk for infections), or neurotoxicity occurs during the first cycle of treatment, a DPD deficiency may be involved (see section 2: Warnings and precautions). Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.
In addition to the above, when Xelcip is used alone, very common side effects, which may affect more than 1 in 10 people are:
-
– abdominal pain
-
– rash, dry or itchy skin
-
– tiredness
-
– loss of appetite (anorexia)
These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Xelcip. This will help reduce the likelihood that the side effect continues or becomes severe.
Other side effects are:
Common side effects (may affect up to 1 in 10 people) include: – decreases in the number of white blood cells or red blood cells (seen in tests)
-
– dehydration, weight loss
-
– sleeplessness (insomnia), depression
-
– headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation),
-
– taste changes
-
– eye irritation, increased tears, eye redness (conjunctivitis)
-
– inflammation of the veins (thrombophlebitis),
-
– shortness of breath, nose bleeds, cough, runny nose
-
– cold sores or other herpes infections
-
– infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)
-
– bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry mouth
-
– skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration, skin loss, skin inflammation, nail disorder
-
– pain in the joints, or in the limbs (extremities), chest or back
-
– fever, swelling in the limbs, feeling ill
-
– problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)
Uncommon side effects (may affect up to 1 in 100 people) include:
-
– blood infection, urinary tract infection, infection of the skin, infections in the nose and throat, fungal infections (including those of the mouth), influenza, gastroenteritis, tooth abscess,
-
– lumps under the skin (lipoma),
-
– decreases in blood cells including platelets, thinning of blood (seen in tests)
-
– allergy
-
– diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides,
-
– confusional state, panic attacks, depressed mood, decreased libido,
-
– difficulty speaking, impaired memory, loss of movement coordination, balance disorder, fainting, nerve damage (neuropathy) and problems with sensation
-
– blurred or double vision,
-
– vertigo, ear pain.
-
– irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction),
-
– blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities), purple spots on the skin
-
– blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up blood, asthma, shortness of breath on exertion,
-
– bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal discomfort, heartburn (reflux of food from the stomach), blood in the stool,
-
– jaundice (yellowing of skin and eyes)
-
– skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain of the face
-
– joint swelling or stiffness, bone pain, muscle weakness or stiffness,
-
– fluid collection in the kidneys, increased frequency of urination during the night, incontinence, blood in the urine, increase in blood creatinine (sign of kidney dysfunction)
-
– unusual bleeding from the vagina
-
– swelling (oedema), chills and rigors
Some of these side effects are more common when Xelcip is used with other medicines for the treatment of cancer. Other side-effects seen in this setting are the following:
Common side effects (may affect up to 1 in 10 people) include:
-
– decrease in blood sodium, magnesium or calcium, increase in blood sugar,
-
– nerve pain,
-
– ringing or buzzing in the ears (tinnitus), loss of hearing,
-
– vein inflammation,
-
– hiccups, change in voice,
-
– pain or altered/abnormal sensation in the mouth, pain in the jaw,
-
– sweating, night sweats,
-
– muscle spasm,
-
– difficulty in urination, blood or protein in the urine,
-
– bruising or reaction at the injection site (caused by medicines given by injection at the same time)
Rare side effects (may affect up to 1 in 1,000 people) include: – narrowing or blockage of tear duct (lacrimal duct stenosis), – liver failure,
-
– inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis),
-
– specific changes in the electrocardiogram (QT prolongation),
-
– certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and bradycardia).
-
– eye inflammation causing eye pain and possibly eyesight problems
-
– inflammation of the skin causing red scaly patches due to an immune system illness
Very rare side effects (may affect up to 1 in 10,000 people) include:
-
– severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes).
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. how to store xelcip
Keep this medicine out of the sight and reach of children.
Store in original pack
Do not use this medicine after the expiry date which is stated on the outer carton, label and blister, after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. contents of the pack and other information
What Xelcip contains
-
– The active substance is capecitabine
o Xelcip 150 mg film-coated tablets
Each film-coated tablet contains 150 mg of capecitabine.
o Xelcip 500 mg film-coated tablets
Each film-coated tablet contains 500 mg of capecitabine.
-
– The other ingredients are:
o Tablet core: lactose monohydrate, microcrystalline cellulose, hypromellose 6 cps, croscarmellose sodium, magnesium stearate
o Tablet coating: hypromellose 15 cps (E464), titanium dioxide (E171), red iron oxide (E172), macrogol
What Xelcip tablet looks like and contents of the pack
Xelcip 150 mg film-coated tablets are pink colored, capsule shaped, biconvex, film coated tablets, debossed with “150”on one side and plain on other side.
Xelcip 500 mg film-coated tablets are pink colored, capsule shaped, biconvex, film coated tablets, debossed with “500” on one side and plain on other side.
For 150 mg : Carton containing blister (PVC/PVDC film and aluminium foil) of 10, 60 tablets.
For 500 mg : Carton containing blister (PVC/PVDC film and aluminium foil) of 4, 120 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and Manufacturer
Marketing authorization holder
Cipla (EU) Limited,
Dixcart House, Addlestone Road,
Bourne Business Park, Addlestone,
Surrey, KT15 2LE, United Kingdom
Manufacturer
S & D Pharma, CZ, spol. s.r.o.
Registered office of the company: P^snicka 22/546, 142 00 Prague 4, Czech Republic
Place of manufacture: Theodor 28, 273 08 Pchery
(PHARMOS a.s. facility), Czech Republic
Cipla (EU) Limited,
Dixcart House, Addlestone Road,
Bourne Business Park, Addlestone,
Surrey, KT15 2LE, United Kingdom
Cipla Europe NV
De Keyserlei 58–60 bus 19,
Antwerpen, 2018, Belgium
This leaflet was last revised in July 2021.
Cipla
Font : Times New Roman (Regular) Times New Roman (Bold)
Proofless
Safety Variation
“UK
Heading : 12pt
Subheading : 10pt
Body text: 9pt
PACKAGING DEVELOPMENT
| Product Name: XELCIP 150mg-500mg film-coated tablets (Safety Variation) | Material No.: 21085210 | Version: 01 | Item: Leaflet | Co-ordinator: Shweta | Artist: Avadhoot | Date: 07/07/2021 | |||||||||||
| Colours: m BLUE WOOL TEST VALUE 5–8 Black (LIGHT FASTENING DATA) | INK: Oil based Ink from DIC OR MICRO | ||||||||||||||||
| Design: Booklet | Supersedes/Reference: 21082777 | Software: Illustrator CC | |||||||||||||||
| Fonts: ------ | Links: NA | ||||||||||||||||
| Actual Size: 210 × 450 mm | Size after folding: 35 × 50 mm | 2D Code: 21085210 | Grain Direction : Parallel to length | Screen : # — | |||||||||||||
| Material: 40 GSM ITC Paper with plain perforated tape | Varnish: --- | Artwork Print Size: | | actual | | scaled | |||||||||||||||
| Path: Avadhoot \ F:\Export\EUROPE\DTM\Capecitabine\UK \ 21085210 XELCIP 150mg-500mg film-coated tablets (Safety Variation) PIL UK.ai | |||||||||||||||||
NO CHANGES IN ARTWORK SHOULD BE DONE BY THE PRINTER
| Checked by | Artist | Cordinator | file loaded in Server | Section Head | ||||||||||||
| Pharma Code 2D Code QR Code Bar Code Artwork Spell check | □□□□□□ | □□□□□□ | |||||||||||||||
DSD-D-20–00154
DSD-D-20–00155